Molecular diagnostics of gliomas: The clinical perspective

Acta Neuropathologica

Volumn 120, Issue 5, 2010, Pages 585-592

  Tabatabai, Ghazaleh ^a   Stupp, Roger ^b   Van Den Bent, Martin J ^c   Hegi, Monika E ^b   Tonn, Jörg C ^d   Wick, Wolfgang ^e   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Clinical neurooncology; Clinical trials; Malignant gliomas; Molecular diagnostic; Prognostic factor

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CILENGITIDE; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; IMATINIB; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; GLIOBLASTOMA; GLIOMA; HEALTH CARE QUALITY; HUMAN; MAINTENANCE THERAPY; MIXED TUMOR; MOLECULAR DYNAMICS; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; TREATMENT DURATION;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; PATHOLOGY, MOLECULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 78149388926     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-010-0750-6     Document Type: Review

References (39)

1. TT Batchelor AG Sorensen E di Tomaso, et al. 2007 AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 83 95 1:CAS:528: DC%2BD2sXhtFClsLc%3D 10.1016/j.ccr.2006.11.021 17222792 (Pubitemid 46075199)
2. AA Brandes E Franceschi A Tosoni ME Hegi R Stupp 2008 Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments Clin Cancer Res 14 957 960 1:CAS:528:DC%2BD1cXhvF2ntL0%3D 10.1158/1078-0432.CCR-07- 1810 18281526 (Pubitemid 351302539)
3. N Butowski SM Chang KR Lamborn, et al. 2010 Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study Neuro-Oncology 12 608 613 1:CAS:528:DC%2BC3cXovFCqurc%3D 10.1093/neuonc/nop070 20156802
4. G Cairncross B Berkey E Shaw, et al. 2006 Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J Clin Oncol 24 2707 2714 1:CAS:528:DC%2BD28XntV2hurg%3D 10.1200/JCO.2005.04.3414 16782910 (Pubitemid 46630566)
5. D Capper S Weissert J Balss, et al. 2009 Monoclonal antibody specific for IDH1 R132H mutation Acta Neuropathol 118 599 601 1:CAS:528:DC%2BD1MXhtlKitLrK 10.1007/s00401-009-0595-z 19798509
6. HJ Dubbink W Taal R van Marion, et al. 2009 IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide Neurology 73 1792 1795 1:CAS:528:DC%2BD1MXhsVaks77K 10.1212/WNL.0b013e3181c34ace 19933982
7. H Friedman M Prados P Wen, et al. 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 4733 4740 1:CAS:528:DC%2BD1MXhtlGgtbbM 10.1200/JCO.2008.19.8721 19720927
8. ME Hegi AC Diserens T Gorlia, et al. 2005 MGMT gene silencing and response to temozolomide in glioblastoma N Engl J Med 352 997 1003 1:CAS:528:DC%2BD2MXit1Wktro%3D 10.1056/NEJMoa043331 15758010 (Pubitemid 40349502)
9. JP Issa 2004 CpG island methylator phenotype in cancer Nat Rev Cancer 4 988 993 1:CAS:528:DC%2BD2cXhtVarsLjK 10.1038/nrc1507 15573120 (Pubitemid 39626222)
10. G Kaloshi A Benouaich-Amiel F Diakite, et al. 2007 Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome Neurology 68 1831 1836 1:CAS:528:DC%2BD2sXltl2itrc%3D 10.1212/01.wnl.0000262034. 26310.a2 17515545 (Pubitemid 46791397)
11. F Keime-Guibert O Chinot L Taillandier, et al. 2007 Radiotherapy for glioblastoma in the elderly N Engl J Med 356 1527 1535 1:CAS:528: DC%2BD2sXkt1Sjtrs%3D 10.1056/NEJMoa065901 17429084 (Pubitemid 46588417)
12. TN Kreisl L Kim K Moore, et al. 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 740 745 1:CAS:528:DC%2BD1MXjsVCjs7o%3D 10.1200/JCO.2008.16.3055 19114704
13. TN Kreisl S Kotliarova JA Butman, et al. 2010 A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas Neuro-Oncology 12 181 189 1:CAS:528:DC%2BC3cXotFKitbg%3D 20150385
14. A Lai E Filka B McGibbon, et al. 2008 Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability Int J Radiat Oncol Biol Phys 71 1372 1380 1:CAS:528:DC%2BD1cXoslWqsLo%3D 18355978
15. Malmstrom A, Grønberg BH, Stupp R et al. (2010) Glioblastoma (GBM) in elderly patients: a randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). J Clin Oncol 28:7s (suppl; abstr. LBA2002)
16. H Noushmehr DJ Weisenberger K Diefes, et al. 2010 Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 510 522 1:CAS:528:DC%2BC3cXmslKqsr0%3D 10.1016/j.ccr.2010.03.017 20399149
17. F Pignatti M Van den Bent D Curran, et al. 2002 Prognostic factors for survival in adult patients with cerebral low grade glioma J Clin Oncol 20 2076 2084 10.1200/JCO.2002.08.121 11956268 (Pubitemid 34408798)
18. DA Reardon KL Fink T Mikkelsen, et al. 2008 Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme J Clin Oncol 26 5610 5617 1:CAS:528: DC%2BD1MXmsVSrsw%3D%3D 10.1200/JCO.2008.16.7510 18981465
19. D Ricard G Kaloshi A Amiel-Benouaich, et al. 2007 Dynamic history of low-grade gliomas before and after temozolomide treatment Ann Neurol 61 484 490 1:CAS:528:DC%2BD2sXnsFKmu74%3D 10.1002/ana.21125 17469128 (Pubitemid 46878776)
20. W Roa PM Brasher G Bauman, et al. 2004 Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial J Clin Oncol 22 1583 1588 1:STN:280:DC%2BD2c3hvF2msA%3D%3D 10.1200/JCO.2004.06.082 15051755 (Pubitemid 41079795)
21. M Sanson Y Marie S Paris, et al. 2009 Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J Clin Oncol 27 4150 4154 1:CAS:528:DC%2BD1MXhtF2jtLrP 10.1200/JCO.2009.21.9832 19636000
22. O Schnell B Krebs J Carlsen, et al. 2009 Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography Neuro Oncol 11 861 870 10.1215/15228517-2009-024 19401596
23. JN Scott PM Brasher RJ Sevick NB Rewcastle PA Forsyth 2002 How often are nonenhancing supratentorial gliomas malignant? A population study Neurology 59 947 949 1:STN:280:DC%2BD38vovVWlsQ%3D%3D 12297589
24. Soffietti R, Baumert B, Bello L et al (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO task force. Eur J Neurol (in press)
25. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma N Engl J Med 352 987 996 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330 15758009 (Pubitemid 40349501)
26. R Stupp ME Hegi WP Mason, et al. 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 1:CAS:528:DC%2BD1MXlsVKhs74%3D 10.1016/S1470-2045(09)70025-7 19269895
27. R Stupp ME Hegi B Neyns, et al. 2010 Phase I//IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J Clin Oncol 28 2712 2718 1:CAS:528:DC%2BC3cXoslyktLs%3D 10.1200/JCO.2009.26.6650 20439646
28. MJ Van den Bent AF Carpentier AA Brandes, et al. 2006 Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial J Clin Oncol 24 2715 2722 10.1200/JCO.2005.04.6078 16782911 (Pubitemid 46630567)
29. MJ Van den Bent HJ Dubbink M Sanson, et al. 2009 MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group study 26951 J Clin Oncol 27 5881 5886 10.1200/JCO.2009.24.1034 19901104
30. MJ van den Bent HJ Dubbink Y Marie, et al. 2010 IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Clin Cancer Res 16 1597 1604 10.1158/1078-0432.CCR-09- 2902 20160062
31. M Weller H Berger C Hartmann, et al. 2007 Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13 6933 6937 1:CAS:528:DC%2BD2sXhtlyit7fL 10.1158/1078-0432.CCR-07-0573 18056167 (Pubitemid 350276872)
32. M Weller J Felsberg C Hartmann, et al. 2009 Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma. A prospective translational study of the German Glioma Network J Clin Oncol 27 5743 5750 1:CAS:528:DC%2BC3cXhtVWisbg%3D 10.1200/JCO.2009.23.0805 19805672
33. M Weller R Stupp G Reifenberger, et al. 2010 MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev Neurol 6 39 51 1:CAS:528:DC%2BC3cXisV2gtA%3D%3D 10.1038/nrneurol.2009.197
34. A Wick C Pascher W Wick, et al. 2009 Rechallenge with temozolomide in patients with recurrent gliomas J Neurol 256 734 741 1:CAS:528: DC%2BD1MXmtVKmsro%3D 10.1007/s00415-009-5006-9 19240962
35. W Wick C Hartmann C Engel, et al. 2009 NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide J Clin Oncol 27 5874 5880 1:CAS:528:DC%2BC3cXhtVWis7g%3D 10.1200/JCO.2009.23.6497 19901110
36. Wick W, Engel C, Combs SE et al (2010) NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). J Clin Oncol 28:7s (suppl; abstr. LBA2001)
37. W Wick VK Puduvalli M Chamberlain, et al. 2010 Enzastaurin versus lomustine in the treatment of recurrent intracranial glioblastoma: a phase III study J Clin Oncol 28 1168 1174 1:CAS:528:DC%2BC3cXktF2ltb4%3D 10.1200/JCO.2009.23.2595 20124186
38. Wick W, Weller M, van den Bent M, Stupp R (2010) Bevacizumab and reccurent malignant gliomas: a European perspective. J Clin Oncol 28:e188-189
39. WKA Yung MD Prados R Yaga-Tur, et al. 1999 Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse J Clin Oncol 17 2762 2771 1:CAS:528: DyaK1MXmtlWru7s%3D 10561351